Physician profile
Megan Ward
NPI 1003653858
$1,025.12
in general payments reported to CMS, 2019-2025
25 companies · $1,025 in 2025
The $1,025 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $1,025.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,025.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,025.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $148.43 | 2025 | Keytruda, Welireg, Reblozyl |
| Janssen Biotech, INC. | $144.17 | 2025 | Darzalex, Talvey, Rybrevant |
| Tersera Therapeutics LLC | $75.26 | 2025 | Zoladex |
| Aveo Pharmaceuticals, INC. | $65.16 | 2025 | |
| Legend Biotech USA INC. | $55.08 | 2025 | Carvykti |
| Pharmaessentia USA Corporation | $54.27 | 2025 | Besremi |
| Geron Corporation | $43.85 | 2025 | Rytelo |
| Regeneron Healthcare Solutions, INC. | $33.08 | 2025 | Libtayo |
| Sun Pharmaceutical Industries INC. | $32.59 | 2025 | |
| Fennec Pharmaceuticals, INC. | $31.58 | 2025 | Fyarro |
| Takeda Pharmaceuticals U.S.A., INC. | $31.44 | 2025 | Fruzaqla |
| Astrazeneca Pharmaceuticals LP | $29.29 | 2025 | Calquence |
| Eisai INC. | $29.03 | 2025 | |
| Genmab U.S., INC. | $27.90 | 2025 | Epkinly |
| Avyxa Pharma, LLC | $26.67 | 2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacosmos Therapeutics INC. | $24.22 | 2025 | Monoferric |
| Exelixis INC. | $23.36 | 2025 | Cabometyx |
| Sobi, INC | $23.03 | 2025 | |
| Corcept Therapeutics | $21.82 | 2025 | Korlym |
| Lilly USA, LLC | $20.36 | 2025 | Jaypirca, Verzenio, Retevmo |
| Agios Pharmaceuticals, INC. | $20.25 | 2025 | Pyrukynd |
| Taiho Oncology, INC. | $17.51 | 2025 | |
| Sumitomo Pharma America, INC. | $17.11 | 2025 | Orgovyx |
| Genentech USA, INC. | $17.07 | 2025 | Tecentriq Hybreza |
| Janssen Scientific Affairs, LLC | $12.59 | 2025 | Rybrevant |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Megan Ward listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.